1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: Subgroup analysis of a randomized phase 3 study (TAGS)
    Journal Article

    Shitara, K.; Doi, T.; Hosaka, H.; Thuss-Patience, P.; Santoro, A.; Longo, F.; Ozyilkan, O.; Cicin, I.; Park, D.; Zaanan, A.; more...
    Gastric Cancer (2022)

    Fulltext@MSK | Save
  • Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8
    Journal Article

    Walle, T.; Kraske, J. A.; Liao, B.; Lenoir, B.; Timke, C.; Von Bohlen und Halbach, E.; Tran, F.; Griebel, P.; Albrecht, D.; Ahmed, A.; more...
    Science Advances (2022)

    Fulltext@MSK | Save
  • Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
    Journal Article

    Shitara, K.; Ajani, J. A.; Moehler, M.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A. C.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer
    Journal Article

    Shepherd, J. H.; Ballman, K.; Polley, M. Y. C.; Campbell, J. D.; Fan, C.; Selitsky, S.; Fernandez-Martinez, A.; Parker, J. S.; Hoadley, K. A.; Hu, Z.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase Ib/II randomized study of RO4929097, a gamma-secretase or notch inhibitor with or without vismodegib, a hedgehog inhibitor, in advanced sarcoma
    Journal Article

    Gounder, M. M.; Rosenbaum, E.; Wu, N.; Dickson, M. A.; Sheikh, T. N.; D'Angelo, S. P.; Chi, P.; Keohan, M. L.; Erinjeri, J. P.; Antonescu, C. R.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomised controlled trial
    Journal Article

    El-Khoueiry, A. B.; Meyer, T.; Cheng, A. L.; Rimassa, L.; Sen, S.; Milwee, S.; Kelley, R. K.; Abou-Alfa, G. K.
    BMC Cancer (2022)

    Fulltext@MSK | Save
  • Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
    Journal Article

    Mazza, G. L.; Petersen, M. M.; Ginos, B.; Langlais, B. T.; Heon, N.; Gounder, M. M.; Mahoney, M. R.; Zoroufy, A. J.; Schwartz, G. K.; Rogak, L. J.; more...
    Quality of Life Research (2022)

    Fulltext@MSK | Save
  • Local therapy outcomes and toxicity from the ATEMPT trial (TBCRC 033): A phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer
    Journal Article

    Bellon, J. R.; Tayob, N.; Yang, D. D.; Tralins, J.; Dang, C. T.; Isakoff, S. J.; DeMeo, M.; Burstein, H. J.; Partridge, A. H.; Winer, E. P.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): A randomized controlled trial
    Journal Article

    Barroso-Sousa, R.; Tarantino, P.; Tayob, N.; Dang, C.; Yardley, D. A.; Isakoff, S. J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; more...
    npj Breast Cancer (2022)

    Fulltext@MSK | Save
  • Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: A randomized phase 3 trial
    Journal Article

    Powles, T.; Yuen, K. C.; Gillessen, S.; Kadel, E. E. 3rd; Rathkopf, D.; Matsubara, N.; Drake, C. G.; Fizazi, K.; Piulats, J. M.; Wysocki, P. J.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save